Article
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2016
Ben-Ami E, Barysauskas C M, von Mehren M, Heinrich M C, Corless C L, Butrynski J E, Morgan J A, Wagner A J, Choy E, Yap J T, Van den Abbeele A D, Solomon S M, Fletcher J A, Demetri G D, George S
Abstract excerpt
BACKGROUND: This investigator-initiated trial provided the justification for the phase III GRID study resulting in worldwide regulatory approval of regorafenib as a third-line therapy for patients with metastatic gastrointestinal stromal tumors (GIST). We report the genotype analyses, long-term safety, and activity results from this initial trial of regorafenib in GIST. PATIENTS AND METHODS: The trial was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.